Grufity logoGrufity logo

Ginkgo Bioworks Holdings, Inc. Stock Research

DNA

1.33USD+0.10(+8.13%)Market Closed

Market Summary

USD1.33+0.10
Market Closed
8.13%

DNA Alerts

DNA Stock Price

DNA RSI Chart

DNA Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-1.03

Price/Sales (Trailing)

4.54

EV/EBITDA

-0.41

Price/Free Cashflow

-7.12

DNA Price/Sales (Trailing)

DNA Profitability

EBT Margin

-670.21%

Return on Equity

-245.97%

Return on Assets

-188.65%

Free Cashflow Yield

-14.04%

DNA Fundamentals

DNA Revenue

Revenue (TTM)

477.7M

Revenue Y/Y

-33.81%

Revenue Q/Q

48.02%

DNA Earnings

Earnings (TTM)

-2.1B

Earnings Y/Y

88.97%

Earnings Q/Q

73.61%

Price Action

52 Week Range

1.174.91
(Low)(High)

Last 7 days

4.7%

Last 30 days

-5%

Last 90 days

-21.3%

Trailing 12 Months

-67%

DNA Financial Health

Current Ratio

11.71

DNA Investor Care

Shares Dilution (1Y)

23.22%

Diluted EPS (TTM)

-1.25

Financials for Ginkgo Bioworks Holdings

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-9.5%477,706,000527,915,000539,127,000438,145,000313,837,000
Operating Expenses-35.8%2,686,658,0004,187,094,0003,571,957,0002,884,012,0002,142,304,000
  S&GA Expenses-35.2%1,429,799,0002,206,982,6671,665,349,333862,952,000-
  R&D Expenses-43.3%1,052,643,0001,856,513,0001,649,954,0001,412,797,0001,149,662,000
EBITDA-15.1%-3,490,597,000-3,033,922,000-2,220,765,145-1,818,701,000-
EBITDA Margin-17.5%-6.61-5.63-5.07-5.80-
Earnings Before Taxes40.0%-2,121,399,000-3,538,153,000-2,971,682,000-2,355,962,000-1,838,122,000
EBT Margin-21.6%-6.70-5.51-5.50-5.86-
Interest Expenses137.9%10,951,0004,603,0002,451,0002,373,000-
Net Income40.4%-2,104,929,000-3,529,041,000-2,961,867,000-2,346,983,000-1,830,047,000
Net Income Margin-21.7%-6.68-5.49-5.48-5.83-
Free Cahsflow-9.9%-344,778,000-313,676,000-311,411,562-310,339,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets35.7%2,5391,8711,9942,0582,071
  Current Assets-0.8%1,4501,4621,5991,7061,723
    Cash Equivalents1.0%1,3161,3031,3771,4931,550
  Inventory-25.5%4.006.008.009.003.00
  Net PPE67.8%315188176149146
  Goodwill109.0%60.0029.0031.0021.0021.00
Liabilities86.3%803431427444504
  Current Liabilities38.6%173125135159135
Shareholder's Equity21.0%1,7361,4351,5671,6141,505
  Retained Earnings-4.1%-4,397-4,226-3,557-2,888-2,297
  Additional Paid-In Capital8.2%6,1365,6695,0984,4713,805
Accumulated Depreciation6.7%83.0078.0070.0061.00-
Shares Outstanding-0.3%1,6311,6361,6071,611-
Minority Interest-100.0%-5.0032.0033.0062.00
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations19.4%-252-313-289-225-253
  Share Based Compensation-43.4%1,9313,4142,8512,2591,606
Cashflow From Investing27.5%-67.39-92.91-76.93-86.20-73.26
Cashflow From Financing799.0%95.00-13.641,5351,5331,534
  Buy BacksNaN%0.000.0025.00--

Risks for DNA

What is the probability of a big loss on DNA?

68.6%


Probability that Ginkgo Bioworks Holdings stock will be more than 20% underwater in next one year

68.6%


Probability that Ginkgo Bioworks Holdings stock will be more than 30% underwater in next one year.

64.7%


Probability that Ginkgo Bioworks Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does DNA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Ginkgo Bioworks Holdings was unfortunately bought at previous high price.

Drawdowns

Returns for DNA

Cumulative Returns on DNA

Which funds bought or sold DNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-23
MetLife Investment Management, LLC
added
3.76
-32,456
41,653
-%
2023-03-17
American Portfolios Advisors
added
6.29
61,926
219,358
0.01%
2023-03-15
B. Riley Wealth Advisors, Inc.
new
-
118,109
118,109
-%
2023-03-13
Claro Advisors LLC
sold off
-100
-238,000
-
-%
2023-03-10
BAILLIE GIFFORD & CO
added
19.65
-224,061,000
412,659,000
0.43%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
23.12
-92,526
184,474
-%
2023-03-08
Capital Asset Advisory Services LLC
unchanged
-
-61,175
71,825
0.01%
2023-03-06
OLD MISSION CAPITAL LLC
new
-
10,962
10,962
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-12.13
-3,000
1,000
-%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
added
42.97
-18,146
61,854
-%

1–10 of 43

Latest Funds Activity

Are funds buying DNA calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own DNA
No. of Funds

Ginkgo Bioworks Holdings News

Best Stocks

Ginkgo Bioworks experiences increase in shares due to positive ....

Best Stocks,
14 hours ago

GuruFocus.com

GINKGO BIOWORKS INVESTIGATION.

GuruFocus.com,
7 days ago

Schedule 13G FIlings of Ginkgo Bioworks Holdings

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
che austin
6.3%
99,857,282
SC 13G/A
Feb 14, 2023
knight thomas f. jr.
5.0%
74,936,116
SC 13G/A
Feb 14, 2023
anchorage capital group, l.l.c.
4.83%
69,904,593
SC 13G/A
Feb 14, 2023
viking global investors lp
9.36%
143,085,126
SC 13G/A
Feb 13, 2023
general atlantic, l.p.
2.4%
32,319,896
SC 13G/A
Feb 09, 2023
vanguard group inc
7.49%
101,521,280
SC 13G
Jan 25, 2023
shetty reshma p.
12.0%
195,788,523
SC 13D/A
Jan 25, 2023
kelly jason r
6.2%
97,017,435
SC 13D/A
Jan 23, 2023
baillie gifford & co
18.03%
244,176,643
SC 13G/A
Jul 01, 2022
viking global investors lp
9.7%
115,084,128
SC 13G

DNA Fair Value

Recent SEC filings of Ginkgo Bioworks Holdings

View All Filings
Date Filed Form Type Document
Mar 31, 2023
4
Insider Trading
Mar 31, 2023
4
Insider Trading
Mar 31, 2023
4
Insider Trading
Mar 30, 2023
144
Notice of Insider Sale Intent
Mar 30, 2023
144
Notice of Insider Sale Intent
Mar 29, 2023
144
Notice of Insider Sale Intent
Mar 29, 2023
144
Notice of Insider Sale Intent
Mar 24, 2023
4
Insider Trading
Mar 24, 2023
4
Insider Trading
Mar 24, 2023
4
Insider Trading

Latest Insider Trading transactions for DNA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-23
Shetty Reshma P.
sold
-47,363
1.258
-37,650
see remarks
2023-03-23
Canton Barry
sold
-47,363
1.258
-37,650
-
2023-03-23
Kelly Jason R
sold
-125,800
1.258
-100,000
see remarks
2023-03-22
Shetty Reshma P.
sold
-48,530
1.289
-37,650
see remarks
2023-03-22
Canton Barry
sold
-48,530
1.289
-37,650
-
2023-03-22
Kelly Jason R
sold
-128,500
1.285
-100,000
see remarks
2023-03-16
Kelly Jason R
sold
-131,500
1.315
-100,000
see remarks
2023-03-16
Canton Barry
sold
-49,509
1.315
-37,650
-
2023-03-16
Shetty Reshma P.
sold
-49,509
1.315
-37,650
see remarks
2023-03-15
Kelly Jason R
sold
-131,700
1.317
-100,000
see remarks

1–10 of 50

Jason Kelly
640
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

DNA Income Statement

2022-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Biosecurity revenue:   
Total revenue$ 477,706$ 313,837$ 76,657
Costs and operating expenses:   
Research and development1,052,6431,149,662159,767
General and administrative expenses1,429,799862,95238,306
Total operating expenses2,686,6582,142,304213,684
Loss from operations(2,208,952)(1,828,467)(137,027)
Other income (expense):   
Interest income20,2628372,582
Interest expense(106)(2,373)(2,385)
(Loss) gain on equity method investments:(43,761)(77,284)(396)
Loss on investments(53,335)(11,543)(3,733)
Change in fair value of warrant liabilities124,97058,6150
Gain on settlement of partnership agreement023,8268,286
Gain on deconsolidation of subsidiaries31,88900
Other income (expense), net7,634(1,733)7,839
Total other income (expense), net87,553(9,655)12,193
Loss before income taxes(2,121,399)(1,838,122)(124,834)
Income tax (benefit) provision(15,027)(1,480)1,889
Net loss(2,106,372)(1,836,642)(126,723)
Loss attributable to non-controlling interest(1,443)(6,595)(114)
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders$ (2,104,929)$ (1,830,047)$ (126,609)
Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders (2):   
Basic$ (1.25)$ (1.35)$ (0.10)
Diluted$ (1.25)$ (1.39)$ (0.10)
Weighted average common shares outstanding (2)   
Basic1,679,061,4651,359,848,8031,274,766,915
Diluted1,679,838,8491,360,373,3431,274,766,915
Comprehensive loss:   
Net loss$ (2,106,372)$ (1,836,642)$ (126,723)
Other comprehensive loss:   
Foreign currency translation adjustment(917)(1,715)
Total other comprehensive loss(917)(1,715)
Comprehensive loss(2,107,289)(1,838,357)(126,723)
Product   
Biosecurity revenue:   
Total revenue35,45523,0408,707
Costs and operating expenses:   
Cost of Biosecurity revenue20,64620,0176,705
Service   
Biosecurity revenue:   
Total revenue298,585177,8088,729
Costs and operating expenses:   
Cost of Biosecurity revenue183,570109,6738,906
Foundry Revenue [Member]   
Biosecurity revenue:   
Total revenue[1]$ 143,666$ 112,989$ 59,221
[1]

(1)

(2)

Includes related party revenue of $38,813, $47,161, and $42,535 for the years ended 2022, 2021, and 2020, respectively.

Amounts for the year ended December 31, 2020 have been retroactively restated for the reverse recapitalization as described in Note 2.

DNA Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 1,315,792$ 1,550,004
Accounts receivable, net80,907131,544
Accounts receivable - related parties1,5584,598
Inventory, net4,3643,362
Prepaid expenses and other current assets47,45833,537
Total current assets1,450,0791,723,045
Property, plant, and equipment, net314,773145,770
Operating lease right-of-use assets400,7620
Investments112,188102,037
Equity method investments1,54313,194
Intangible assets, net111,04121,642
Goodwill60,21021,312
Other non-current assets88,72543,990
Total assets2,539,3212,070,990
Current liabilities:  
Accounts payable10,4518,189
Deferred revenue (includes $10,309 and $12,502 from related parties)47,81733,240
Accrued expenses and other current liabilities114,69493,332
Total current liabilities172,962134,761
Non-current liabilities:  
Deferred rent, net of current portion018,746
Deferred revenue, net of current portion (includes $131,188 and $148,319 from related parties)174,767155,991
Operating lease liabilities, non-current413,2560
Lease financing obligation 22,283
Warrant liabilities10,868135,838
Other non-current liabilities31,19135,992
Total liabilities803,044503,611
Commitments and contingencies (Note 11)
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued00
Common stock $0.0001 par value (Note 12)190161
Additional paid-in capital6,136,3783,804,844
Accumulated deficit(4,397,659)(2,297,925)
Accumulated other comprehensive loss(2,632)(1,715)
Total Ginkgo Bioworks Holdings, Inc. stockholders’ equity1,736,2771,505,365
Non-controlling interest062,014
Total stockholders’ equity1,736,2771,567,379
Total liabilities and stockholders’ equity$ 2,539,321$ 2,070,990